Viridian Therapeutics' (VRDN) Lumvoa is emerging as a "credible" competitor to Amgen's (AMGN) Tepezza in thyroid eye disease, as it offers comparable efficacy and a shorter treatment course, BofA Securities said in a note Thursday.
Early demand has been strong since Lumvoa's July launch and the drug generated $25 million in Q3 revenue, well above Street consensus of about $5 million, with more than 100 patients enrolled in the therapy, according to the note.
BofA said its doctor checks suggest Lumvoa could become the leading treatment choice in thyroid eye disease, potentially capturing more than 70% of market share within two years.
The investment firm said it expects permanent J-code on Jan 1, 2027, to drive uptake and forecasts $1.3 billion in peak sales, contributing $24 per share.
With subcutaneous elegrobart also in development for chronic thyroid eye disease, Viridian Therapeutics could become the market leader, the firm said.
BofA Securities initiated coverage of Viridian Therapeutics with a buy rating and a price target of $47.
Price: 30.61, Change: +0.49, Percent Change: +1.63
Comments